癌症疫苗:開發平台評估與到2018年為止的市場預測 是由出版商GlobalData在2012年01月所出版的。
這份英文市場調查報告書包含Pages: 147 價格從美金3500起跳。
本報告提供癌疫苗的研究以及開發的最新趨勢調查，進行相關的市場預測，癌症疫苗概論，全球及主要7個國家的市場規模測量與預測(2005∼2018年)，競爭結構、臨床實驗進行狀況相關開發平台的評估，今後的市場趨勢，相關企業資訊及交易趨勢，彙整以上種種資訊，為您概述為以下內容。
第1章 目錄
第2章 簡介
- 概要
- 各種各樣的癌症的免疫學
- 癌症的發病率·死亡率:美國
- 癌症的發病率·死亡率:歐洲(EU5個國家)
- 癌症的發病率·死亡率:日本
- 癌症疫苗
- 預防癌症疫苗
- Gardasil(四價人類乳突病毒疫苗(類型6/11/16/18)的基因重組型)
- Cervarix (二價人類乳突病毒疫苗(類型16/18)的基因重組型)
- 子宮頭部癌症:概論
- 癌症治療疫苗
- 未來的癌症疫苗
- 現在可以利用的癌症的治療方法的缺點
- 未來的癌症病毒的優點
- 該報告內容架構
第3章 市場特徵
- 市場規模實際成果值·預測值:全球(2005∼2018年)
- 市場規模實際成果值·預測值:美國(2005∼2018年)
- 市場規模實際成果值·預測值:法國(2005∼2018年)
- 市場規模實際成果值·預測值:德國(2005∼2018年)
- 市場規模實際成果值·預測值:義大利(2005∼2018年)
- 市場規模實際成果值·預測值:西班牙(2005∼2018年)
- 市場規模實際成果值·預測值:英國(2005∼2018年)
- 市場規模實際成果值·預測值:日本(2005∼2018年)
- 市場促進·阻礙因素
- 機會及未飽和需求
- 主要的結論
第4章 競爭力評估
- 概要
- 主要的市售產品的產品簡介
- Gardasil(四價人類乳突病毒疫苗(類型6/11/16/18)的基因重組型)
- Cervarix (二價人類乳突病毒疫苗(類型16/18)的基因重組型)
- Provenge(sipuleucelT)
- 主要的結論
第5章 開發平台評估
- 概要
- 策略性開發平台評估
- 開發平台分析:臨床實驗的各開發階段
- 預防癌症疫苗:階段III開發平台
- 預防癌症疫苗:階段II開發平台
- 預防癌症疫苗:階段I開發平台
- 預防癌症疫苗:前臨床開發平台
- 癌症治療疫苗:階段III開發平台
- 癌症治療疫苗:階段II/III開發平台
- 癌症治療疫苗:階段II開發平台
- 癌症治療疫苗:階段I/II開發平台
- 癌症治療疫苗:階段I開發平台
- 癌症治療疫苗:前臨床開發平台
- 技術趨勢分析用的組成架構
- 疫苗的不同種類的開發平台
- 臨床實驗階段有潛力的預防癌症疫苗
- 臨床實驗階段有潛力的癌症疫苗(預防癌症疫苗)簡介
- 臨床實驗階段有潛力的癌症治療疫苗
- 臨床實驗階段有潛力的癌症疫苗(癌症治療疫苗)簡介
- Stimuvax
- OncoVAX
- OncoVEX (GM-CSF)
- Lucanix (belagenpumatucel-L)
- Trovax
- HyperAcute Pancreas
- Allovectin-7
- IMA901
- BiovaxID
- MAGE-A3 ASCI
- GV1001
- 主要的結論
第6章 臨床實驗藍圖
- 各地區·各國的臨床實驗數(美國·EU5個國家·日本)
- 各階段臨床實驗數
- 各篩檢階段臨床實驗數
- 贊助商的整體情形
- 有潛力的贊助商
- 參加癌症疫苗臨床實驗的前幾名企業
第7章 策略性評估
第8章 今後的參與市場企業
- 簡介
- 企業簡介
- Merck & Co., Inc. (Merck)
- Vical Incorporated
- Vaccinogen
- Newlink Genetics Corporation
- Biovest International(Accentual Biopharmaceuticals, Inc.的子公司)
- Oxford Biomedica
- Immatics biotechnologies GmbH
- NovaRx Corporation
- Oncothyreon
- 其他的企業
第9章 許可證·合作交易
第10章 附錄
圖表一覽
Abstract
Summary
GlobalData, the industry analysis specialist, has released its new report, "Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global cancer vaccines market. The report identifies the key trends shaping and driving the global cancer vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global cancer vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global cancer vaccines market was worth $3,483.0m in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006-2010. During 2010-2018, the market is expected to record a CAGR of 12.7%, to reach $9,077.9m by 2018. This high growth is attributed to the increasing patient population of cancer. Cancer is the most common cause of death globally. The high growth rate is due to expected introduction of promising vaccines during the forecast period. The cancer vaccines market is divided into the prophylactic cancer vaccines market and the therapeutic cancer vaccines market. The prophylactic cancer vaccines market experienced high growth in the historic period due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant). Gardasil was approved in the US and Europe in 2006 and in Japan in 2011. Similarly, Cervarix was launched in Europe in 2008 and in the US and Japan in 2009. The Prophylactic cancer vaccines market is expected to grow in the forecast period to 2018 due to the label extension of Gardasil. In December 2010, the FDA approved a new indication for Gardasil, anal cancer and anal intraepithelial neoplasia grades 1, 2 and 3 in males and females between the age of 9 and 26, which is expected to drive the prophylactic cancer vaccine market. The expected launch of the first-in-class vaccine, V503 in 2014, is also expected to drive the prophylactic cancer vaccine market during the forecast period. V503 is a multivalent vaccine and is believed to provide greater protection from many strains of HPV (human papillomavirus) than the existing vaccines in the market, which are either tetravalent or bivalent, thereby lowering the risk of cervical cancer. The prophylactic cancer vaccine market will grow during the forecast period but will not show significant growth because V503 will uptake the market of Gardasil and there will be little change in the market.
The cancer vaccines therapeutic market is expected to show high growth in the forecast period to 2018 due to the expected launch of first-in-class therapeutic cancer vaccines. Presently, there is only one therapeutic cancer vaccine, Provenge, which is a dendritic cell vaccine for advanced prostate cancer patients. Provenge received approval in April 2010 and is presently available only in the US. Dendreon is expecting to file Provenge in Europe in early 2012 and is expected to be launched on the market by mid-2013, which will help drive the therapeutic cancer vaccine market during the forecast period. The expected launch of first-in-class vaccines for different types of cancer during the forecast period to 2018 is expected to drive the cancer vaccines therapeutics market.
These drugs include:
Allovectin-7 for Melanoma
BiovaxId (Idiotype vaccine therapy) for follicular non-Hodgkin lymphoma in Europe and the US,
Oncovex for melanoma
Stimuvax (BLP25 liposome vaccine) for unresectable stage III NSCLC (non-small cell lung cancer).
Due to the launch of first-in-class vaccines during the forecast period the therapeutic cancer vaccines market is expected to show high growth.
Scope
The report provides information on the key drivers and challenges of the cancer vaccines market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) cancer vaccines market revenues data from 2005 to 2010, forecast for seven years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major vaccines such as tumor cell vaccines, antigen vaccine, peptide vaccine, DNA vaccine, dendritic cell vaccine ,vector based vaccine, BCG vaccine, Multipeptide vaccine, Autologous tumor derived immunoglobulin idiotype vaccine, Recombinant vaccine, Autologous tumor-derived heat shock protein peptide-complex, Synthetic Peptide vaccine, Conjugate vaccine, Adenovirus vaccine, Liposome vaccine, protein idiotype vaccine, a novel therapeutic vaccine platform, tumor antigen RNA-transfected dendritic cells, Recombinant Modified Vaccinia Ankara (MVA)-Based Vaccine, heated-killed yeast-based vaccine etc.
- Analysis of the current and future competition in the seven key countries cancer vaccines market. Key market players covered are Merck, NovaRx Corporation, NewLink Genetics Corporation, Bavarian Nordic, immatics biotechnologies GmbH, Oxford BioMedica, Biovex, Vaccinogen, Biovest International, Vaccinogen and GlaxoSmithKline.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the cancer vaccines market.
- Analysis of key recent licensing and partnership agreements in cancer vaccines market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global cancer vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global cancer vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global cancer vaccines market landscape? - Identify, understand and capitalize.
Table of Contents
1. Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Cancer Vaccines - Introduction
- 2.1 Overview
- 2.2 Epidemiology of Various Cancers
- 2.2.1 Cancer Incidence and Mortality in the US
- 2.2.2 Cancer Incidence and Mortality in Europe (EU5)
- 2.2.3 Cancer Incidence and Mortality in Japan.
- 2.3 Cancer Vaccines
- 2.4 Prophylactic Cancer Vaccines
- 2.4.1 Gardasil (Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant)
- 2.4.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant)
- 2.4.3 Cervical Cancer: An Introduction
- 2.5 Therapeutic Cancer Vaccines
- 2.5.1 Provenge
- 2.5.2 Prostate Cancer: An Introduction
- 2.5.3 Metastatic Prostate Cancer
- 2.6 Future of Cancer Vaccines
- 2.6.1 Drawbacks of Available Cancer Therapies
- 2.6.2 Benefits of the Upcoming Cancer Vaccines
- 2.7 GlobalData Pipeline Report Guidance
3. Cancer Vaccines - Market Characterization
- 3.1 Cancer Vaccines Market Size (2005-2010) - Global
- 3.2 Cancer Vaccines Market Forecast (2010-2018) - Global
- 3.3 Cancer Vaccines Market Size (2006-2010) - The US
- 3.4 Cancer Vaccines Market Forecast (2010-2018) - The US
- 3.5 Cancer Vaccines Market Size (2005-2010) - France
- 3.6 Cancer Vaccines Market Forecast (2010-2018) - France
- 3.7 Cancer Vaccines Market Size (2005-2010) - Germany
- 3.8 Cancer Vaccines Market Forecast (2010-2018) - Germany
- 3.9 Cancer Vaccines Market Size (2005-2010) - Italy
- 3.10 Cancer Vaccines Market Forecast (2010-2018) - Italy
- 3.11 Cancer Vaccines Market Size (2005-2010) - Spain
- 3.12 Cancer Vaccines Market Forecast (2010-2018) - Spain
- 3.13 Cancer Vaccines Market Size (2005-2010) - The UK
- 3.14 Cancer Vaccines Market Forecast (2010-2018) - The UK
- 3.15 Cancer Vaccines Market Size (2006-2010) - Japan
- 3.16 Cancer Vaccines Market Forecast (2010-2018) - Japan
- 3.17 Drivers and Barriers for the Cancer Vaccines Market
- 3.17.1 Drivers for the Cancer Vaccines Market
- 3.17.2 Barriers for the Cancer Vaccines Market
- 3.18 Opportunity and Unmet Need Analysis
- 3.19 Key Takeaway
4. Cancer Vaccines - Competitive Assessment
- 4.1 Overview
- 4.1.1 Strategic Competitor Assessment
- 4.2 Product Profiles for the Major Marketed Products in the Cancer Vaccines Therapeutics Market
- 4.2.1 Gardasil (HPV Quadrivalent (Type 6, 11, 16 and 18) Vaccine, Recombinant)
- 4.2.2 Cervarix (Human Papillomavirus Bivalent (Type 16, 18) Vaccine, Recombinant)
- 4.2.3 Provenge (sipuleucel-T)
- 4.3 Key Takeaway
5. Cancer Vaccines - Pipeline Assessment
- 5.1 Overview
- 5.2 Strategic Pipeline Assessment
- 5.3 Cancer Vaccines Pipeline - Pipeline by Phases of Development
- 5.3.1 Prophylactic Cancer Vaccines - Phase III Pipeline
- 5.3.2 Prophylactic Cancer Vaccines - Phase II Pipeline
- 5.3.3 Prophylactic Cancer Vaccines - Phase I Pipeline
- 5.3.4 Prophylactic Cancer Vaccines - Preclinical Pipeline
- 5.3.5 Therapeutics Cancer Vaccines- Phase III Pipeline
- 5.3.6 Therapeutics Cancer Vaccines - Phase II/III Pipeline
- 5.3.7 Therapeutics Cancer Vaccines - Phase II Pipeline
- 5.3.8 Therapeutics Cancer Vaccines - Phase I/II Pipeline
- 5.3.9 Therapeutics Cancer Vaccines- Phase I Pipeline
- 5.3.10 Therapeutic Cancer Vaccines Market - Preclinical Pipeline
- 5.3.11 Technology Trends Analytic Framework
- 5.4 Cancer Vaccines Market - Pipeline by Vaccine Type
- 5.5 Cancer Vaccines - Promising Prophylactic Vaccines under Clinical Development
- 5.6 Profile of Promising Vaccines Under Clinical Development (Prophylactic Cancer Vaccine)
- 5.7 Cancer Vaccines - Promising Therapeutic Vaccines under Clinical Development
- 5.8 Vaccines Profiles of Promising Vaccines Under Clinical Development (Therapeutic Cancer Vaccines)
- 5.8.1 Stimuvax
- 5.8.2 OncoVAX
- 5.8.3 OncoVEX (GM-CSF)
- 5.8.4 Lucanix (belagenpumatucel-L)
- 5.8.5 Trovax
- 5.8.6 HyperAcute Pancreas
- 5.8.7 Allovectin-7
- 5.8.8 IMA901
- 5.8.9 BiovaxID
- 5.8.10 MAGE-A3 ASCI
- 5.8.11 GV1001
- 5.9 Key Takeaway
6. Cancer Vaccines - Clinical Trials Mapping
- 6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
- 6.2 Clinical Trials by Phase
- 6.3 Clinical Trials by Trial Status
- 6.4 Prominent Sponsors
- 6.5 Top Companies Participating in Cancer Vaccines Clinical Trials
7. Cancer Vaccines - Strategic Assessment
- 7.1 Key Events Impacting the Future Market
- 7.2 Cancer Vaccines: Implications for Future Market Competition
8. Cancer Vaccines - Future Players
- 8.1 Introduction
- 8.2 Company Profiles
- 8.2.1 Merck & Co., Inc. (Merck).
- 8.2.2 Vical Incorporated
- 8.2.3 Vaccinogen
- 8.2.4 Newlink Genetics Corporation
- 8.2.5 Biovest International (Subsidiary of Accentual Biopharmaceuticals, Inc.)
- 8.2.6 Oxford Biomedica
- 8.2.7 Immatics biotechnologies GmbH
- 8.2.8 NovaRx Corporation
- 8.2.9 Oncothyreon
- 8.2.10 Other Companies in the Cancer Vaccines Market
9. Cancer Vaccines - Licensing and Partnership Deals
10. Cancer Vaccines - Appendix
- 10.1 Market Definitions
- 10.2 Abbreviations
- 10.3 Methodology
- 10.3.1 Coverage
- 10.3.2 Secondary Research
- 10.3.3 Forecasting
- 10.3.4 Primary Research
- 10.3.5 Expert Panel Validation
- 10.4 Contact Us
- 10.5 Disclaimer
- 10.6 Bibliography
List of Tables
- Table1: Cancer Incidence and Mortality in the US, 2011
- Table 2: Cancer Incidence and Mortality in Europe (EU5), 2010
- Table 3: Cancer Incidence and Mortality in Japan, 2010
- Table 4: Difference Between Autologous and Allogenic Tumor Cell Vaccines.
- Table 5: Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
- Table 6: Cancer Vaccines Market, Global, Forecast, Revenue ($m), 2010-2018
- Table 7: Cancer Vaccines Market, The US, Revenue ($m), 2006-2010
- Table 8: Cancer Vaccines Market, The US, Forecasts, Revenue ($m), 2010-2018
- Table 9: Cancer Vaccines Market, France, Revenue ($m), 2006-2010
- Table 10: Cancer Vaccines Market, France, Forecasts, Revenue ($m), 2010-2018
- Table 11: Cancer Vaccines Market, Germany, Revenue ($m), 2006-2010
- Table 12: Cancer Vaccines Market, Germany, Forecasts, Revenue ($m), 2010-2018
- Table 13: Cancer Vaccines Market, Italy, Revenue ($m), 2006-2010
- Table 14: Cancer Vaccines Market, Italy, Forecasts, Revenue ($m), 2010-2018
- Table 15: Cancer Vaccines Market, Spain, Revenue ($m), 2006-2010
- Table 16: Cancer Vaccines Market, Spain, Forecast Revenue ($m), 2010-2018
- Table 17: Cancer Vaccines Market, The UK, Revenue ($m), 2006-2010
- Table 18: Cancer Vaccines Market, The UK, Forecasts ($m), 2010-2018
- Table 19: Cancer Vaccines Market, Japan, Forecasts ($m), 2010-2018
- Table 20: Gardasil Approvals and Fillings
- Table 21: Prophylactic Cancer Vaccines- Phase III Pipeline, 2011
- Table 22: Prophylactic Cancer Vaccines- Phase II Pipeline, 2011
- Table 23: Prophylactic Cancer Vaccines- Phase I Pipeline, 2011
- Table 24: Prophylactic Cancer Vaccines-Preclinical Pipeline, 2011
- Table 25: Therapeutic Cancer Vaccines- Phase III Pipeline, 2011
- Table 26: Therapeutic Cancer Vaccines- Phase II/III Pipeline, 2011
- Table 27: Therapeutic Cancer Vaccines- Phase II Pipeline, 2011
- Table 28: Therapeutic Cancer Vaccines- Phase I/II Pipeline, 2011
- Table 29: Therapeutic Cancer Vaccines- Phase I Pipeline, 2011
- Table 30: Therapeutic Cancer Vaccines- Preclinical Pipeline, 2011
- Table 31: Prophylactic Cancer Vaccines -Promising Vaccines Under Clinical Development, 2011
- Table 32: Therapeutic Cancer Vaccines -Promising Vaccines Under Clinical Development, 2011
- Table 33: Cancer Vaccines - Clinical Trials by Country, 2011
- Table 34: Cancer Vaccines - Clinical Trials by Phase, 2011
- Table 35: Cancer Vaccines - Clinical Trials by Status, 2011
- Table 36: Cancer Vaccines - Prominent Sponsors, 2011
- Table 37: Cancer Vaccines - Top Companies Participating in Therapeutics Clinical Trials, 2011
- Table 38: Vical- Cancer vaccines, Pipeline, 2011
- Table 39: Vical- Cancer vaccines, Pipeline, 2011
- Table 40: Vaccinogen- Cancer vaccines Pipeline, 2011
- Table 41: Newlink Genetics Corporation, Cancer Vaccines Pipeline, 2011
- Table 42: Biovest International, Cancer vaccines Pipeline, 2011
- Table 43: Oxford BioMedica, Pipeline, 2011
- Table 44: Immatics biotechnologies , Cancer Vaccines Pipeline, 2011
- Table 45: NovaRx Corporation,Cancer Vaccines Pipeline, 2011
- Table 46: Oncothyreon, Cancer Vaccines Pipeline, 2011
- Table 47: Cancer Vaccines Market - Future Players
- Table 48: Cancer Vaccines, Global, Deals
List of Figures
- Figure 1: Mechanism of Action of Tumor Cell Vaccine
- Figure 2: Immunity Induction Pathway by DNA Vaccines.
- Figure 3: Manner in which Therapeutic Cancer Vaccines are Given in Clinics
- Figure 4: Cancer Vaccines Market, Global, Revenue ($m), 2006-2010
- Figure 5: Prophylactic Cancer Vaccines Market, Global, Forecast ($m), 2010-2018
- Figure 6: Therapeutic Cancer Vaccines Market, Global, Forecast ($m), 2010-2018
- Figure 7: Cancer Vaccines Market, The US, Revenue ($m), 2006-2010
- Figure 8: Prophylactic Cancer Vaccines Market, The US, Forecast ($m), 2010-2018
- Figure 9: Therapeutic Cancer Vaccines Market, The US, Forecast ($m), 2010-2018
- Figure 10: Cancer Vaccines Market, France, Revenue ($m), 2006-2010
- Figure 11: Prophylactic Cancer Vaccines Market, France, Forecast ($m), 2010-2018
- Figure 12: Therapeutic Cancer Vaccines Market, France, Forecast ($m), 2010-2018
- Figure 13: Cancer Vaccines Market, Germany, Revenue ($m), 2006-2010
- Figure 14: Prophylactic Cancer Vaccines Market, Germany, Forecast ($m), 2010-2018
- Figure 15: Therapeutic Cancer Vaccines Market, Germany, Forecast ($m), 2010-2018
- Figure 16: Cancer Vaccines Market, Italy, Revenue ($m), 2006-2010
- Figure 17: Prophylactic Cancer Vaccines Market, Italy, Forecast ($m), 2010-2018
- Figure 18: Therapeutic Cancer Vaccines Market, Italy, Forecast ($m), 2010-2018
- Figure 19: Cancer Vaccines Market, Spain, Revenue ($m), 2006-2010
- Figure 20: Prophylactic Cancer Vaccines Market, Spain, Forecast ($m), 2010-2018
- Figure 21: Therapeutic Cancer Vaccines Market, Spain, Forecast ($m), 2013-2018
- Figure 22: Cancer Vaccines Market, The UK, Revenue ($m), 2006-2010
- Figure 23: Prophylactic Cancer Vaccines Market, The UK, Forecast ($m), 2010-2018
- Figure 24: Therapeutic Cancer Vaccines Market, The UK, Forecast ($m), 2013-2018
- Figure 25: Prophylactic Cancer Vaccines Market, Japan, Forecast ($m), 2010-2018
- Figure 26: Therapeutic Cancer Vaccines Market, Japan, Forecast ($m), 2014-2018
- Figure 27: Opportunity and Unmet Need in the Prophylactic Cancer Vaccines Market, 2011
- Figure 28: Opportunity and Unmet Need in the Therapeutic Cancer Vaccines Market, 2011
- Figure 29: Prophylactic Cancer Vaccines - Strategic Competitor Assessment, 2011
- Figure 30: Therapeutic Cancer Vaccines - Strategic Competitor Assessment, 2011
- Figure 31: Prophylactic Cancer Vaccines - Pipeline by Phases of Development, 2011
- Figure 32: Therapeutic Cancer Vaccines - Pipeline by Phase of Development, 2011
- Figure 33: Prophylactic Cancer Vaccines - Technology Trends Analytics Framework, 2011
- Figure 34: Prophylactic Cancer Vaccines - Technology Trends Analytics Framework - Description, 2011
- Figure 35: Therapeutic Cancer Vaccines- Technology Trends Analytics Framework - Description, 2011
- Figure 36: Therapeutic Cancer Vaccines- Technology Trends Analytics Framework - Description, 2011
- Figure 37: Prophylactic Cancer Vaccines - Pipeline by Vaccine Type, 2011
- Figure 38: Therapeutic Cancer Vaccines - Pipeline by vaccine type, 2011
- Figure 39: Cancer Vaccines - Clinical Trials by Country, 2011
- Figure 40: Cancer Vaccines - Clinical Trials by Phase, 2011
- Figure 41: Cancer Vaccines - Clinical Trials by Status, 2011
- Figure 42: Cancer Vaccines - Overall Sponsors, 2011
- Figure 43: Cancer Vaccines - Prominent Sponsors, 2011
- Figure 44: Cancer Vaccines - Prominent Sponsors, 2011
- Figure 45: Cancer Vaccines Market, Drivers and Barriers ,2011
- Figure 46: Implications for Future Market Competition in the Prophylactic Cancer Vaccines Market, 2011
- Figure 47: Implications for Future Market Competition in the Therapeutic Cancer Vaccines Market, 2011
- Figure 48: Cancer Vaccines Market - Pipeline by Company, 2011
- Figure 49: GlobalData Market Forecasting Model
|
